Welcome to our dedicated page for Cardiac Biotech Solutions news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cardiac Biotech Solutions stock.
Cardiac Biotech Solutions, Inc. (CBSC) is a medical technology company that regularly issues news updates about its non-invasive ambulatory cardiac monitoring products, regulatory milestones, and international distribution activities. Its disclosures focus on the MyCardia AT and CardioHolter AT cardiac event monitoring platforms, which combine wearable devices with AWS Cloud-based connectivity and mobile applications.
News coverage for CBSC often highlights regulatory approvals and submissions, such as FDA clearance for MyCardia AT in the United States and a Medical Device License from Health Canada for the CardioHolter AT in Canada. The company also reports on progress toward regulatory clearance in China through collaborations with licensed NMPA medical device manufacturers and hospital-based clinical field testing.
Investors and healthcare observers following CBSC’s news can expect announcements about distribution agreements and purchase orders in key markets. Recent releases have described exclusive distribution arrangements with partners in Canada, Central America, and South America, as well as initial purchase orders for thousands of devices that support the company’s combined device sales and recurring rental revenue model.
Additional CBSC news items address corporate developments, including the company’s name change from CB Scientific, Inc. to Cardiac Biotech Solutions, Inc., voluntary delisting from the OTCQB Venture Market while continuing to trade on the OTC Pink Open Market, and updates on financing efforts and technology initiatives. For readers interested in how remote cardiac monitoring technologies are being deployed across multiple regions and regulatory environments, the CBSC news feed provides ongoing insight into the company’s product launches, partnerships, and strategic steps in the ambulatory cardiac monitoring space.
Cardiac Biotech Solutions (OTCID: CBSC) has activated its China production pipeline for the MyCardia AT cardiac event monitor via partner Ebulent Medical (Shenzhen). CBSC delivered printed circuit assemblies, components, and accessories to Ebulent and opened a secure cloud data room containing the full manufacturing package for NMPA-compliant Device History File creation. Ebulent is configuring production and aims to complete an initial manufacturing run by month-end, after which devices will undergo in-hospital clinical field testing in China. Following successful validation, CBSC and partners will submit the final regulatory dossier to the NMPA advisory board for commercial clearance.
Cardiac Biotech Solutions (OTCID: CBSC) has secured a Medical Device License from Health Canada for its MyCardia AT device, now rebranded as CardioHolter AT. The company's Canadian distributor, Your Heart Protector Corp., has placed an initial $375,000 USD order for 1,000 devices.
The CardioHolter AT will be manufactured and distributed through CBSC's partner Nasiff Associates, operating under ISO 13485 certification. The company has implemented a monthly rental program generating recurring revenue through device access, AWS Cloud-based monitoring platform, and mobile applications.
CBSC has already obtained regulatory clearance in the United States and is pursuing approval in China, advancing its global commercialization strategy for the cardiac monitoring platform.
Cardiac Biotech Solutions (OTCID: CBSC) has secured a $375,000 purchase order from Noventis Medical for 2,500 MyCardia AT Cardiac Event Monitoring devices at $150 per unit. The order will be fulfilled in two phases: 1,000 units immediately and 1,500 units within 90 days.
CBSC has also launched a recurring revenue model through a monthly rental program that includes device usage, AWS Cloud-based monitoring software, and patient applications. The revenue sharing structure allocates one-third of monthly rental fees to CBSC and two-thirds to distributor partners.
The company's MyCardia AT platform combines wearable technology with cloud connectivity and mobile applications, with regulatory clearances in the US and pending approvals in Canada and China.
Cardiac Biotech Solutions (OTCID: CBSC) has secured a five-year exclusive distribution agreement with Noventis Medical for its cardiac monitoring products in Costa Rica, Panama, Colombia, and Argentina. The contract is valued at $600,000 USD and includes a right of first refusal for future distribution opportunities in other Central and South American countries.
The agreement centers on CBSC's MyCardia AT event monitoring platform, which combines wearable technology with AWS Cloud connectivity and mobile applications. The company has already obtained regulatory clearance in the U.S. and is pursuing additional approvals in Canada and China as part of its global expansion strategy.
Cardiac Biotech Solutions, Inc. (OTC PINK:CBSC) announced its official name change from CB Scientific, Inc., effective May 7, 2025. The company, which specializes in non-invasive cardiac monitoring products, will retain its CBSC ticker symbol and CUSIP number. The company recently received FDA clearance for its MyCardia AT event monitor and is pursuing regulatory approvals in China through the NMPA and in Canada via Your Heart Protector Corp.
The MyCardia AT cardiac event monitor features a lightweight design and integrates with the AWS Cloud-based MyCardia portal and mobile applications across iOS and Android platforms. The company is working with international distribution partners in Southeast Asia, Hong Kong, and Macau for product launch.
CB Scientific Inc. (CBSC) has officially launched its next generation MyCardia AT cardiac monitor in partnership with contract manufacturer Datrix, This FDA-cleared device is designed for the company's international distribution network in SE Asia, Hong Kong, and Macau.
The MyCardia AT offers an improved patient monitoring experience with its lightweight, easy-to-wear design and flexible options to transmit event recordings via iOS or Android smartphones using the MyCardia app. The device helps physicians detect cardiac arrhythmias in patients with intermittent symptoms during a 30-day monitoring period, addressing a critical health concern as ischemic heart disease deaths have increased from 2.7 million to 9.1 million since 2000.
CBSC is strategically enhancing its cardiac monitoring portfolio by integrating the device with its existing AWS Cloud-based MyCardia portal and smartphone applications. Distributors in Malaysia, Singapore, Thailand, Indonesia, Hong Kong, and Macau will begin registering the device with regulatory agencies, with plans to expand to China and Canada pending regulatory approvals.
CB Scientific (OTC PINK:CBSC), a company specializing in non-invasive ambulatory cardiac monitoring products and services, has appointed William "Trip" Thomas as its new Chief Financial Officer, effective October 1, 2024. This appointment follows the resignation of Brooke Turk, who stepped down on September 30, 2024. The company clarified that Turk's departure was not due to any disagreement or conflict.
Mr. Thomas brings a strong educational background to his new role, holding a Bachelor of Science in Accounting from the University of Tampa and a Bachelor of Science in Agribusiness from the University of Florida. Additionally, he is a licensed Certified Public Accountant in the State of Florida, further solidifying his qualifications for the position.
CB Scientific (OTC PINK:CBSC), a company focused on non-invasive ambulatory cardiac monitoring products, has announced its voluntary delisting from the OTCQB Venture Market. This decision aims to preserve capital for implementing the company's business plan. Importantly, CBSC's common stock will continue trading on the OTC Pink Open Market, allowing shareholders to maintain their ability to trade shares in the public market. The company states that it plans to re-engage an auditor and apply for uplisting when certain milestones are achieved and conditions are appropriate.
Summary not available.
Summary not available.